Diffusion-weighted imaging for identifying patients at high risk of tumor recurrence following liver transplantation

Yi-Hsuan Chuang1, Hsin-You Ou1, Chun-Yen Yu1, Chao-Long Chen2, Ching-Chun Weng1, Leo Leung-Chit Tsang1, Hsien-Wen Hsu1, Wei-Xiong Lim1, Tung-Liang Huang1 and Yu-Fan Cheng1*

Abstract

Background: Tumor recurrence is the major risk factor affecting post-transplant survival. In this retrospective study, we evaluate the prognostic values of magnetic resonance (MR) diffusion-weighted imaging (DWI) in liver transplantation for hepatocellular carcinoma (HCC).

Methods: From April 2014 to September 2016, 106 HCC patients receiving living donor liver transplantation (LDLT) were enrolled. Nine patients were excluded due to postoperative death within 3 months and incomplete imaging data. The association between tumor recurrence, explant pathologic findings, and DWI parameters was analyzed (tumor-to-liver diffusion weighted imaging ratio, DWI T/L; apparent diffusion coefficients, ADC). The survival probability was calculated using the Kaplan–Meier method.

Results: Sixteen of 97 patients (16%) developed tumor recurrence during the follow-up period (median of 40.9 months; range 5.2–56.5). In those with no viable tumor (n = 65) on pretransplant imaging, recurrence occurred only in 5 (7.6%) patients. Low minimum ADC values (p = 0.001), unfavorable tumor histopathology (p < 0.001) and the presence of microvascular invasion (p < 0.001) were risk factors for tumor recurrence, while ADC mean (p = 0.111) and DWI T/L (p = 0.093) showed no significant difference between the groups. An ADC min ≤ 0.88 × 10⁻³ mm²/s was an independent factor associated with worse three-year recurrence-free survival (94.4% vs. 23.8%) and overall survival rates (100% vs. 38.6%).

Conclusions: Quantitative measurement of ADC min is a promising prognostic indicator for predicting tumor recurrence after liver transplantation.

Keywords: Diffusion weighted imaging, ADC value, Tumor recurrence

Background

Liver transplantation (LT) is the preferred treatment for selected patients with hepatocellular carcinoma (HCC) and end-stage liver disease, given that it removes the tumor as well as the diseased liver. The Milan criteria [1], which considers the size and number of the tumors, was used for decades as the standard to determine transplant eligibility. Unfortunately, recurrence rates have been reported to be as high as 26% [2]. There is growing evidence that tumor biological behavior is a prognostic factor. Criteria applying various indicators such as alpha-fetoprotein (AFP), protein induced by vitamin K absence or antagonists-II (PIVKA-II), and the neutrophil–lymphocyte ratio (NLR) have been published [3–6]. Several studies have also confirmed that poor tumor differentiation and vascular invasion are correlated with early recurrence and worse outcomes [7, 8]. However, these tumor factors can only be obtained via explant pathology and thus may not be useful preoperatively.

Diffusion-weighted imaging (DWI) is a distinct functional imaging technique, allowing qualitative and quantitative assessment of the diffusion properties of various types of tissue. In highly cellular tumors, decreased
extracellular space and increased tortuosity of the extra-
cellular matrix hinder the mobility of water molecules.
The apparent diffusion coefficient (ADC) values calcu-
lated from DWI data reflect the tumor microenviron-
ment and have the potential to predict tumor histopathology.

The aim of this study was to investigate the associ-
ation between pretransplant magnetic resonance (MR)-
DWI indices and tumor factors with post-transplant
recurrence.

Methods
Institutional review board approval was obtained for this
retrospective study of patient medical records; informed
consent was waived.

Study population
From April 2014 to September 2016, 240 patients con-
secutively underwent living donor liver transplantation
(LDLT) at our institution. Of these, 106 had a confirmed
diagnosis of HCC and five of them had separate intrahe-
patic cholangiocarcinoma (I-CC) or combined hepato-
cellular cholangiocarcinoma (cHCC-CC) in same liver
after histological examination of the explant. Based on
the MR imaging performed in 2 months prior to trans-
plantation, all patients met the University of California
San Francisco (UCSF) criteria [9]. We used AFP > 200
ng/mL as a cutoff [10, 11]. AFP elevation was a relative
contraindication, and locoregional therapy, including ra-
diofrequency ablation (RFA) and transarterial chemoem-
bolization (TACE), were employed upon recognition of
AFP elevation.

Pretransplant clinical parameters such as gender, age,
underlying liver disease, model of end-stage liver disease
(MELD) score, serum AFP level, and MR imaging data
(number of tumors, tumor size, and DWI indices) were
collected. The pathological findings analyzed were histo-
logic differentiation and the presence of microvascular
invasion. Five patients were excluded from the study due
to postoperative death and four patients did not have
DWI data. The median follow-up period was 40.9
months (range 5.2–56.5).

MR imaging protocols
All MR images were acquired on a 1.5 T scanner
(Discovery MR450; GE Healthcare, Milwaukee, WI,
USA) and a twelve-channel body array coil for signal
reception.

The MR protocols were the following: breath-hold in-
phase and opposed-phase fast spoiled gradient-echo T1
weighted imaging; breath-hold fast spin-echo (FSE) T2-
weighted imaging; single shot FSE heavily T2-weighted
imaging with fat suppression; and diffusion-weighted im-
aging using SE single-shot echo-planar technique with
b-values of 0 and 400 s/mm² (repetition time/echo time
(TR/TE): 2400/44; slice thickness/gap: 5/1 mm; matrix:
80 × 128). ADC maps were calculated automatically.
Dynamic images using fat-suppressed T1-weighted
gradient-echo images with a three-dimensional (3D)
acquisition sequence (liver acquisition with volume
acceleration [LAVA]) were obtained at 30 s, 60 s, and 3
min after IV administration of 0.2 mmol/kg gadopente-
tate dimeglumine. The images were acquired in the
transverse plane and had a section thickness of 5 mm
(TR/TE: 3.4/1.6; flip angle: 12°; matrix: 288 × 192).

Imaging analysis
MRI reports were interpreted by experienced radiolo-
gists (Cheng, Tsang, and Ou). Quantitative measure-
ments were performed on the diffusion-weight imaging
and ADC maps. The tumor-to-liver signal intensity
(DWIT/L) ratio was calculated by dividing the signal
intensity of the tumor by that of the liver. With respect
to the mean and lowest ADC values of the tumor
(ADCmean, ADCmin), the regions of interest were manu-
ally placed at its maximum cross section of each viable
tumor on a single slice, referencing T2-weighted and
contrast-enhanced T1-weighted transverse images
(Figs. 1, 2 and 3).

Statistical analysis
Statistical analysis was performed using commercially
available software (MedCalc, version 18.11, Ostend,
Belgium). Clinicopathologic factors were compared be-
tween the nonrecurrence and recurrence groups. We
used the Student’s t-test for continuous variables and
the chi-square test for categorical variables. Cox propor-
tional hazards regression was performed. Recurrence-
free survival and overall survival rates were determined
using the Kaplan–Meier method. The receiver operating
characteristic curves for quantitative DWI indices were
derived. All the p-values were two-sided, and p < 0.05
was considered statistically significant.

Results
Patient characteristics
The clinical data are summarized in Table 1. Sixty-five
men and 32 women were included in this study. The
mean age at transplant was 55.6 years. Eighty-eight
(90%) patients had either hepatitis B virus (HBV) or
hepatitis C virus (HCV) infection. Eighty-two patients
(84%) had hepatectomy, RFA, or TACE before trans-
plantation. Five patients met the UCSF criteria after the
downstaging procedure. Tumor recurrence was observed
in 16 cases (17%).
Fig. 1  MR imaging in a 61-year-old woman. Pathologically confirmed grade 4 HCC. Dotted circles in a DWI and b ADC map show the placement of regions of interest. c T2-weighted imaging shows high signal intensity of the tumor. d Postcontrast T1-weighted image shows heterogeneous arterial enhancement with intralesional low SI area.

Fig. 2  MR imaging in a 60-year-old man who underwent DEB-TACE procedure. Pathologically confirmed grade 4 HCC with 40% tumor necrosis. Dotted circles show the placement of regions of interest. a DWI and b ADC map show restricted diffusion area in the segment VIII tumor. c T2-weighted imaging. d Postcontrast T1-weighted image shows mildly enhancing viable tumor. ADCmin of tumor was $0.84 \times 10^{-3} \text{ mm}^2/\text{s}$.
Tumor recurrence and risk factors

AFP level (15.03 ± 21.60 vs. 19.02 ± 28.85, \( p = 0.526 \)) and largest tumor size (2.83 ± 1.48 vs. 3.15 ± 1.77, \( p = 0.596 \)) were not significantly different between nonrecurrence and recurrence groups (Table 2). Observation of no viable tumor on the imaging before the transplant indicated a lower risk of tumor recurrence (\( p < 0.001 \)).

Among the DWI parameters, only the minimum ADC value was a relevant factor (1.07 ± 0.21 vs. 0.78 ± 0.19, \( p = 0.001 \)). The optimal cutoff value for ADC_{min} was \( \leq 0.88 \times 10^{-3} \text{ mm}^2/\text{s} \), and the area under the receiver operating characteristic curve (AUC) was 0.818 (95% confidence interval, 0.642–0.932; Fig. 4). According to the multivariable analysis, as shown in Table 3, ADC_{min} ≤ 0.88 × 10^{-3} mm^2/s and the presence of microvascular invasion were independent factors, exhibiting hazard ratios of 13.10 (\( p = 0.022 \)) and 4.49 (\( p = 0.026 \)).

Association between DWI parameters and tumor factors

Three of 3 grade 3–4 HCC patients (100%), one of two I-CCC patients (50%), and two of 3 cHCC patients (67%) suffered from tumor recurrence. There was no relationship between the tumor-to-liver DWI ratio (DWIT/L) and the risk factors analyzed, including unfavorable histopathology (\( p = 0.359 \)) and microvascular invasion (\( p = 0.942 \)). Also, the mean ADC value did not reach statistical significance (\( p = 0.301 \) and 0.686). The minimum ADC value was found to be much lower in these aggressive tumors (Table 4).
Fourteen patients had low-ADC tumors (ADC \text{min} \leq 0.88 \times 10^{-3} \text{mm}^2/\text{s}) showing significantly worse recurrence-free survival (RFS) and overall survival (OS) rates (Fig. 5). The high-ADC group had a 94.4% one-year RFS rate, compared to 57.1% in the low-ADC group. The three-year RFS rates were 94.4 and 23.8%, and the OS rates were 100 and 38.6%.

Discussion

The results of this study demonstrate the preoperative factors that predict post-transplant outcomes. Our data suggested that the absence of a viable tumor on preoperative imaging was related to lower odds of recurrence (7.6% vs. 34.3%, \( p < 0.001 \)). Similarly to previous studies, neo-adjuvant locoregional therapies were recommended, since these decreased the dropout rates and improved survival [12, 13]. Yao et al. [14] reported an improvement in post-transplant survival for those who received bridging therapy in the subgroup with pT2 and pT3 HCC. The five-year recurrence-free survival was 93.8% versus 80.6%. Furthermore, unsuccessful therapy may indicate the aggressiveness of tumors [15]. The use of pretransplant elevated alpha-fetoprotein level as a predictor of poor prognosis has been increasingly recognized. The upper cutoff values published in several studies vary widely, between 20 ng/mL and 1000 ng/mL [4, 5, 10, 11, 16, 17]. In our practice, we set a cutoff value of 200 ng/mL as an exclusion criterion for transplantation and implemented bridging/downstaging protocols to reduce the tumor burden. Despite this restrictive policy, the recurrence rate remained unsatisfactory, at 17%. Therefore, more detailed information is required for candidate selection.

For patients within UCSF criteria, the minimum ADC values of tumors were significantly lower in the recurrence group (0.78 ± 0.19 vs. 1.07 ± 0.21, \( p = 0.001 \)). Multivariate analysis revealed that an ADC \text{min} \leq 0.88 \times 10^{-3} \text{mm}^2/\text{s} was an independent predictor of tumor recurrence (HR = 13.10, \( p = 0.022 \)). DWI combined with

| Variable | Nonrecurrence (\( n = 81 \)) | Recurrence (\( n = 16 \)) | \( P \) |
|----------|-----------------------------|---------------------------|------|
| Preoperatively available data | | | |
| AFP level (ng/mL) | 15.03 ± 21.60 | 19.02 ± 28.85 | 0.526 |
| Pre-LT treatment | | | 0.721 |
| Yes | 68 | 14 | |
| No | 13 | 2 | |
| Tumors detected on MRI | | | < 0.001 |
| Numbers | | | |
| No viable tumor | 60 | 5 | |
| Within UCSF criteria | 21 | 11 | |
| Largest tumor size (cm) | 2.83 ± 1.48 | 3.15 ± 1.77 | 0.596 |
| Quantitative indices | | | |
| \( \text{DWI}_{T/L} \) | 1.31 ± 0.36 | 1.56 ± 0.41 | 0.093 |
| ADC_{\text{mean}} \times 10^{-3} \text{mm}^2/\text{s} | 1.50 ± 0.27 | 1.32 ± 0.30 | 0.111 |
| ADC_{\text{min}} \times 10^{-3} \text{mm}^2/\text{s} | 1.07 ± 0.21 | 0.78 ± 0.19 | 0.001 |
| Postoperatively available data | | | < 0.001 |
| Histopathologic features | | | |
| Hepatocellular carcinoma | | | |
| Grade 1–2 | 79 | 10 | |
| Grade 3–4 | 0 | 3 | |
| HCC + I-CC | 1 | 1 | |
| HCC + cHCC-CC | 1 | 2 | |
| Microvascular invasion | | | < 0.001 |
| No | 72 | 7 | |
| Yes | 9 | 9 | |

Data are presented as numbers or mean ± SD

AFP Alpha-fetoprotein, \( \text{DWI}_{T/L} \) Tumor-to-liver diffusion weighted imaging ratio, ADC Apparent diffusion coefficient, I-CC Intrahepatic cholangiocarcinoma, cHCC-CC Combined hepatocellular cholangiocarcinoma

ADC_{\text{min}} correlation with post-transplant outcome

Fourteen patients had low-ADC tumors (ADC_{\text{min}} \leq 0.88 \times 10^{-3} \text{mm}^2/\text{s}) showing significantly worse recurrence-free survival (RFS) and overall survival (OS) rates (Fig. 5). The high-ADC group had a 94.4% one-year RFS rate, compared to 57.1% in the low-ADC group. The three-year RFS rates were 94.4 and 23.8%, and the OS rates were 100 and 38.6%.
ADC mapping has been evaluated as a useful biomarker for tumor featuring and monitoring [18]. ADC$_{\text{min}}$ might better reflect the viable solid part of the tumor than ADC$_{\text{mean}}$, because increased ADC can be caused by tumor necrosis and arterial reperfusion after TACE. Nakanishi et al. [19] reported that ADC$_{\text{min}}$ was significantly lower in patients with early recurrence (0.64 ± 0.24 × 10$^{-3}$ mm$^2$/s, DWI with b values of 50 and 1000 s/mm$^2$) after hepatic resection. Lee et al. [20] retrospectively analyzed 114 single HCC patients and found that low ADC$_{\text{min}}$ (0.773 × 10$^{-3}$ mm$^2$/s, DWI with b values of 0 and 800 s/mm$^2$) was a poor prognostic indicator for RFS. Of particular note is that the cutoff ADC values reported vary between studies. This might be because different study groups use MR scanners of different vendors and specific scan parameters.

Poor tumor differentiation and vascular invasion have been established as major determinants of worse post-liver transplantation (LT) outcomes [21, 22]. In our study, we included two I-CCs and three cHCC-CCs. Vilchez et al. [23], in their analysis of the United Network for Organ Sharing database, found a five-year OS of 40% in cHCC-CC patients, compared to 62% in HCC patients ($p = 0.002$). Another systematic review, by Magistri et al. [24], concluded that LT should be avoided in the management of cHCC-CC. I-CC is typically a contraindication for LT because of inferior survival rates. However, an accurate radiological diagnosis can be difficult, owing to their heterogeneous features. We defined Grade 3–4 HCC, I-CC, and cHCC-CC as unfavorable tumors based on the high recurrence rates (100, 50, and 67%, respectively). Our data demonstrated a good correlation between the minimum ADC value and unfavorable tumors (1.00 ± 0.26 vs. 0.83 ± 0.06, $p = 0.004$). The result confirmed the prior studies, showing an inverse relationship

ADC Apparent diffusion coefficient, MVI Microvascular invasion
*Grade 3–4 HCC, I-CC and cHCC-CC

---

**Table 3 Multivariate analysis of prognostic factors associated with tumor recurrence**

| Variable                        | HR (95% CI) | P     |
|---------------------------------|-------------|-------|
| ADC$_{\text{min}}$ ≤ 0.88 × 10$^{-3}$ mm$^2$/s | 13.10 (1.43–119.54) | 0.022 |
| Unfavorable histopathology*     | 4.02 (0.99–16.33) | 0.051 |
| Presence of MVI                 | 4.49 (1.19–16.89) | 0.026 |

ADC$_{\text{min}}$ = minimum apparent diffusion coefficient.
Table 4 Comparison of DWI indices in tumor histopathological findings

|                | Favorable tumor | Unfavorable tumor | P       | Favorable tumor | Unfavorable tumor | P       |
|----------------|-----------------|-------------------|---------|-----------------|-------------------|---------|
| ADCmin         | 1.00 ± 0.26     | 0.83 ± 0.06       | 0.004   | 1.03 ± 0.23     | 0.83 ± 0.24       | 0.041   |
| ADCmean        | 1.46 ± 0.31     | 1.32 ± 0.18       | 0.301   | 1.42 ± 0.32     | 1.47 ± 0.22       | 0.686   |
| DWIT/L         | 1.37 ± 0.39     | 1.53 ± 0.38       | 0.359   | 1.39 ± 0.40     | 1.41 ± 0.39       | 0.942   |

Data are presented as numbers or mean ± SD.

ADC: Apparent diffusion coefficient, DWI: Tumor-to-liver diffusion weighted imaging ratio, MVI: Microvascular invasion.

*aGrade 3–4 HCC, I-CC and cHCC-CC.

Fig. 5 Kaplan–Meier survival analysis according to ADCmin. a One-year and three-year RFS rates were 94.4% vs. 57.1 and 94.4% vs. 23.8%, respectively, for patients with low-ADC and high-ADC tumors. b OS rates were 100 and 38.6% for the same two groups.
between tumor grade and ADC value. Poorly differentiated HCC shows more restricted diffusion because of its high cellular density, while the ADC values of I-CC tend to be lower due to the presence of abundant desmoplastic stroma in the tumor. But little validation of the range of ADC values specific for I-CC has been documented.

Although macrovascular invasion can be detected with imaging studies, the preoperative prediction of microvascular invasion (MVI) remains elusive. Suh et al. [25] proposed that low ADC values could be applied to the preoperative assessment of MVI, using a cutoff value of 1.11 × 10⁻³ mm²/s. Our data also showed a significantly lower ADCmin in tumors with MVI (1.03 ± 0.23 vs. 0.83 ± 0.24, p = 0.041). One possible explanation for this finding was the change in microcapillary perfusion. Another possible mechanism was described by Okamura et al. [26], during which they used a higher b-value (1000³/mm²) and found that restriction of molecular diffusion occurred via an unknown mechanism.

Based on our results, a cutoff value of 0.88 × 10⁻³ mm²/s for ADCmin can be recommended for predicting tumor recurrence. The RFS was significantly shorter in the low-ADC group than in the high-ADC group, with a one-year RFS of 57.1 and 94.4% in these two groups, respectively. The overall survival rates were 38.6 and 100%. Low-ADC tumors presented more aggressive biological behavior, which resulted in early recurrence following LT. Apart from tumor morphology evaluated according to the Milan and UCSF criteria, the minimum ADC value of the tumor should be considered as a prognostic factor before deciding on operative management with LT.

Conclusions
Tumor biology is the most important predictor for post-LT outcome. A low minimum ADC value of viable tumor is associated with higher recurrence after LT and poor survival. Preoperative MR diffusion-weighted imaging therefore provides effective information for the selection of LT candidates.

Abbreviations
ADC: Apparent diffusion coefficients; AFP: Alpha-fetoprotein; chHCC-CC: Combined hepatocellular cholangiocarcinoma; DW: Diffusion-weighted imaging; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; I-CC: Intrahepatic cholangiocarcinoma; LDLT: Living donor liver transplantation; MELD: Model of end-stage liver disease; MVI: Microvascular invasion; OS: Overall survival; RFA: Radiofrequency ablation; RFS: Recurrence-free survival; TACE: Transarterial chemoembolization; UCSF: University of California San Francisco

Acknowledgements
This work was supported by grants from Chang Gung Memorial Hospital (CMRPG8G1552), and grant MOST 107-2314-B-182A-060-MY2 from the Ministry of Science and Technology, R.O.C.
hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer. 2004;112(1):44–50.

11. Jeng YM, Chang CC, Hu FC, Chou HY, Kao HL, Wang TH, et al. RNA-binding protein insulin-like growth factor II miRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology. 2008;48(4):118–27.

12. Agopian VG, Morshedli MM, McWilliams J, Harlander-Locke MP, Markovic D, Zarrinparsa H, et al. Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients. Ann Surg. 2015;262(3):536–45.

13. Habibollahi P, Shamchi SP, Choi JM, Gade TP, Stavropoulos SW, Hunt SJ, et al. Association of complete radiologic and pathologic response following locoregional therapy before liver transplantation with long-term outcomes of hepatocellular carcinoma: a retrospective study. J Vasc Interv Radiol. 2019;30(3):323–9.

14. Yao FY, Kinkhabwala M, Laberge JM, Bass NM, Brown R. Jr, Kerlan R, et al. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant. 2005;5(4 Pt 1):795–804.

15. Sandow T, Arndt SE, Albar AA, DeVun DA, Kirsch DS, Gimenez JM, et al. Assessment of response to transcatheter arterial chemoembolization with doxorubicin-eluting microspheres: tumor biology and hepatocellular carcinoma recurrence in a 5-year transplant cohort. Radiology. 2018;286(3):1072–83.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions